Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental biologic CND319 takes first steps toward taming autoimmune diseases

NCT ID NCT07712939

Recruiting now Disease control Sponsor: Candid Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage study tests an experimental drug called CND319 in healthy volunteers and people with rheumatoid arthritis or Sjögren's syndrome. The main goal is to check safety and how the body processes the drug. Researchers will also look for early signs that it might help control these autoimmune conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental biologic drug called CND319
What this could lead to
If successful, this could lead to a new treatment option for rheumatoid arthritis and Sjögren's syndrome.
What could go wrong
This is an early, first-in-human trial focused on safety, so the drug may not prove effective or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS STUDY RHEUMATOID ARTHRITIS SJOGREN'S SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Candid Clinical Site

    RECRUITING

    Melbourne, Victoria, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.